Using patient-derived organoids to personalize ovarian cancer treatments
Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA)
This study is testing if using tiny lab-grown versions of ovarian cancer tumors from patients can help doctors find the best treatments for them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Centro di Riferimento Oncologico - Aviano Academic / other |
| Locations | 1 site (Aviano, Pordenone) |
| Trial ID | NCT06229522 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance ovarian cancer therapies by utilizing patient-derived organoids to test the sensitivity of tumors to various treatments. By correlating the treatment responses observed in these organoids with clinical outcomes in real-world patients, the research seeks to identify predictive biomarkers that could guide therapy choices. The study focuses on patients with ovarian cancer who provide tumor samples for analysis, allowing for a personalized approach to treatment. The ultimate goal is to improve survival rates and treatment efficacy for ovarian cancer patients.
Who should consider this trial
Good fit: Ideal candidates for this study are female patients aged 18 and older who have been diagnosed with ovarian cancer and can provide a tumor sample for research.
Not a fit: Patients who are pregnant, breastfeeding, or have a history of other malignancies in the last five years may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized treatment options for ovarian cancer patients.
How similar studies have performed: While the use of patient-derived organoids is a promising approach, it is still relatively novel and has not been extensively tested in similar studies for ovarian cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Signed informed consent form; 2. Female sex; 3. Age ≥18 years; 4. Diagnosis of ovarian cancer; 5. Availability of tumor sample or ascites that is planned to be stored in the Institutional Biobank for research purpose Exclusion Criteria: 1. Patients for which the tumor/ascites biobanking process could compromise the diagnostic assessments; 2. Pregnancy or breast-feeding 3. History of concomitant or previous malignancy in the last 5 years
Where this trial is running
Aviano, Pordenone
- Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS — Aviano, Pordenone, Italy (Recruiting)
Study contacts
- Principal investigator: Vincenzo Canzonieri, MD — Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS
- Study coordinator: Vincenzo Canzonieri, MD
- Email: vcanzonieri@cro.it
- Phone: 0434659618
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.